VANGUARD GROUP INC 13D and 13G filings for Lexeo Therapeutics, Inc. Common Stock:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-03-27 10:16 am Sale | 2026-03-13 | 13G | LEXEO THERAPEUTICS INC LXEO | VANGUARD GROUP INC | 0 0.000% | -3,894,310 (Position Closed) | Filing |
| 2026-01-30 2:18 pm Purchase | 2025-12-31 | 13G | LEXEO THERAPEUTICS INC LXEO | VANGUARD GROUP INC | 3,894,310 5.330% | 3,894,310 (New Position) | Filing |